For laboratory research use only. Not for human or veterinary use.

Same-day dispatch on orders before 4 PM ET · Support

Liraglutide: origin, structure and research history

Research Library › Incretin & Amylin

Liraglutide is a synthetic analogue of human GLP-1 that shares 97% of its amino-acid sequence with the native hormone and carries a 16-carbon fatty acid (palmitic acid) attached through a glutamic acid spacer. It was developed by Novo Nordisk, which published the underlying chemistry in 2000, and the FDA first approved it in January 2010 as Victoza for type 2 diabetes. As of October 2026 it is FDA-approved in branded and generic products, and in April 2026 the FDA proposed excluding it from the 503B bulks list for compounding.

Key facts

TypeSynthetic, acylated GLP-1 analogue (peptide)
Other namesNN2211; brands Victoza and Saxenda
Developed byNovo Nordisk A/S, Denmark
First described2000, Journal of Medicinal Chemistry paper on long-acting GLP-1 derivatives
Designed targetGLP-1 receptor; 97% sequence homology to human GLP-1(7-37)
Regulatory status (Oct 2026)FDA-approved as Victoza (2010) and Saxenda (2014); generic versions approved from Dec 2024; FDA proposed in April 2026 to exclude it from the 503B bulks list

Who developed it

Liraglutide was developed by Novo Nordisk in Denmark. In 2000, a team led by Lotte Bjerre Knudsen published a series of fatty-acid-modified GLP-1 derivatives in the Journal of Medicinal Chemistry, describing chemistry designed to give the hormone a longer duration of action [1]. The compound that became liraglutide carried the development code NN2211.

Liraglutide became the company’s first approved GLP-1 analogue. Novo Nordisk’s later work on semaglutide, a second-generation acylated analogue published in 2015, drew directly on this experience with fatty-acid-modified GLP-1 derivatives [2].

Structure and design

Native GLP-1 is broken down within minutes in the body, which limited early research use of the hormone itself. Liraglutide’s designers made two changes to address this. First, they replaced lysine with arginine at position 34. Second, they attached a C-16 fatty acid, palmitic acid, to the lysine at position 26 through a glutamic acid spacer [3].

The FDA label describes the result as 97% homologous to human GLP-1(7-37) [3]. The fatty acid was intended to promote reversible binding to albumin, a design approach that Novo Nordisk later refined in semaglutide [1, 2].

Research history

  • 2000: Novo Nordisk publishes potent long-acting GLP-1 derivatives [1]
  • 25 January 2010: FDA approves Victoza for type 2 diabetes [3, 4]
  • 23 December 2014: FDA approves Saxenda for chronic weight management in adults [5]
  • 23 December 2024: FDA approves the first generic of Victoza, from Hikma [6]
  • 28 August 2025: Teva announces FDA approval of a generic of Saxenda [7]

Regulatory status as of October 2026

Liraglutide is an FDA-approved active ingredient, marketed by Novo Nordisk as Victoza and Saxenda and, since late 2024, available as FDA-approved generic products [3, 5, 6, 7]. When the FDA announced the first generic in December 2024, it noted that liraglutide injection was then in shortage [6].

On 30 April 2026 the FDA proposed excluding liraglutide, together with semaglutide and tirzepatide, from the 503B bulks list. That list governs which bulk substances outsourcing facilities may use to compound drugs. The agency said it found no clinical need for such compounding; comments closed on 29 June 2026 [8]. As of October 2026 no final determination had been announced.

The FDA’s general position is that compounded GLP-1 products are not reviewed by the agency for safety, effectiveness or quality before marketing, and that compounding is appropriate only when an approved drug cannot meet a patient’s medical need or is not commercially available [9].

About this reference page

Kalibra Labs does not currently supply Liraglutide. This page is published as a neutral scientific and regulatory reference. Browse the Incretin & Amylin guide or the FDA Peptide Regulatory Tracker.

Frequently asked questions

Who developed liraglutide?

Liraglutide was developed by Novo Nordisk; the chemistry behind it was published by Knudsen and colleagues in 2000 [1].

When was liraglutide approved by the FDA?

The FDA approved liraglutide on 25 January 2010 as Victoza for type 2 diabetes, and on 23 December 2014 as Saxenda for chronic weight management [4, 5].

Is there a generic liraglutide?

Yes. The FDA approved the first generic referencing Victoza in December 2024, and Teva announced approval of a generic referencing Saxenda in August 2025 [6, 7].

What changes distinguish liraglutide from natural GLP-1?

Liraglutide has arginine in place of lysine at position 34 and a palmitic acid chain attached to lysine 26 through a glutamic acid spacer [3].

Can liraglutide be compounded?

In April 2026 the FDA proposed excluding liraglutide from the 503B bulks list used by outsourcing facilities; no final decision had been announced as of October 2026 [8].

Sources

  1. Knudsen LB, Nielsen PF, Huusfeldt PO, et al., Agersø H. Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. J Med Chem. 2000;43(9):1664–1669. doi:10.1021/jm9909645. Link
  2. Lau J, Bloch P, Schäffer L, et al., Kruse T. Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. J Med Chem. 2015;58(18):7370–7380. doi:10.1021/acs.jmedchem.5b00726. Link
  3. Novo Nordisk. VICTOZA (liraglutide) injection, prescribing information (Initial U.S. approval 2010; sections 11 and 12.1). Drugs@FDA, NDA 022341. Link
  4. The Pharma Letter. FDA approves Novo Nordisk's new type 2 diabetes drug Victoza. 26 Jan 2010. Link
  5. Novo Nordisk A/S. Saxenda (liraglutide 3 mg) approved by FDA. Company announcement, 23 Dec 2014. Link
  6. U.S. FDA. FDA approves first generic of once-daily GLP-1 injection to lower blood sugar in patients with type 2 diabetes. Press announcement, 23 Dec 2024. Link
  7. Teva Pharmaceutical Industries. Teva announces FDA approval and launch of generic Saxenda (liraglutide injection). Press release, 28 Aug 2025. Link
  8. U.S. FDA. FDA proposes to exclude semaglutide, tirzepatide, and liraglutide on 503B bulks list. Press announcement, 30 Apr 2026. Link
  9. U.S. FDA. FDA's concerns with unapproved GLP-1 drugs used for weight loss (updated 1 Oct 2026). Link

Regulatory information current as of October 2026. Reviewed by the Kalibra Labs editorial team.

Kalibra Labs does not supply this compound. This page is a scientific, historical and regulatory reference only; it is not medical advice and makes no claim about use in people or animals.

0
Your Cart
Empty CartYour cart is emptyReturn to Shop
Scroll to Top